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Abstract 
 
The recreational use of various stimulant drugs has been implicated in the development of 
movement disorders through dysregulation of the dopaminergic and serotoninergic 
neurotransmitter systems. The present study investigated psychomotor differences in current 
and former recreational stimulant drug users compared to non-using controls. Sixty 
participants comprised three groups: 20 current stimulant drug users (CSU: 11 males, age= 
31.4(9.1)), 20 former stimulant drug users (FSU: 5 males, age= 39.1(8.5)), and 20 non-user 
controls (NUC: 5 males, age= 35.7(16.4)). Psychomotor arm steadiness for each participant 
was assessed with a wrist-attached accelerometer during five arm positions with eyes open 
and then eyes closed. Arm-drop of arm position was indicated by the Arm Longitudinal 
Rotation Axis (ALoRA), and tremor was indicated by the overall Vector of Dynamic Body 
Acceleration (VeDBA). Overall, CSU performed the most poorly on ALoRA (p < 0.05) and 
VeDBA indices (p < 0.05), and FSU perform almost as poorly on VeDBA indices (p < 0.05), 
compared to NUC. It was concluded that stimulant drug use, primarily MDMA and 
amphetamine, may result in acute stimulant-induced tremor as well as long-term 
proprioceptive deficits in terms of arm-droop.  
 
 
Keywords: accelerometry, MDMA, ecstasy, amphetamine, psychomotor, tremor, abstinence  
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Introduction 
Consumption of recreational drugs has been implicated in the development of 
movement disorders such as akathisia, ataxia, dyskinesia and motor tremor1,2 by disrupting 
the dopamine and serotonin neurotransmitter systems3-10. Since the symptoms associated with 
these various movement disorders can appear acutely (whilst on drug), sub-acutely (days or 
weeks after drug ingestion), or tardively (months or years after initial exposure to drug) 
following regular or repetitive exposure11,12, they can have a significant impact on users’ 
quality of life.  
Several studies have shown that immediately after ingesting the synthetic, 
psychoactive drug 3,4-methylenedioxymethamphetamine (MDMA), participants describe 
acute side effects including motor tics, twitches, tremors, shakes, muscular pain, unconscious 
arm movements, numbness and tingling sensations10,13,14. In an Internet survey of 282 
recreational MDMA users, 14% of novice users (1-9 lifetime occasions), 20% of moderate 
users (10-99 lifetime occasions) and 38% of experienced users (+100 lifetime occasions) 
reported increased tremors and/or twitches15. In a study of children whose mothers used 
MDMA during their first trimester of pregnancy, there were significant psychomotor delays at 
4- and 12-months post-partum16. The potential causative factors may include both 
neurotransmitters and neurohormones, since recreational MDMA has also been shown to 
increase levels of the stress hormone cortisol17.  
Using accelerometry, stimulant drug users’ current micro- and macro-movement 
abilities can be assessed18-20, which in turn allows for the investigation of movement 
abnormalities as a potential marker of motor circuitry abnormalities and the later development 
of movement disorder20. Empirical research investigating the effect of stimulants on motor 
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function using accelerometry is limited. We have previously used accelerometry to identify 
micro-movements related to caffeine withdrawal and caffeine consumption21. Further, we 
have presented evidence of marked differences in psychomotor control – specifically ‘tremor’ 
values (vectorial dynamic acceleration19) – in MDMA users when they hold their arms 
horizontally18.  
Flavel, Koch, White, Todd 20 measured the degree of finger tremor for abstinent 
amphetamine, MDMA and cannabis users compared to non-drug users and observed 
significant impairment in MDMA users. Todd, Flavel, Koch, White 22 compared index finger 
motion and tremor during rest and movement between abstinent MDMA users, abstinent 
methamphetamine users, abstinent cannabis users, and non-user controls. Using 
accelerometry, the authors noted that only abstinent MDMA users displayed abnormally large 
motion tremors during movement compared to abstinent methamphetamine users, abstinent 
cannabis users and non-user controls. Bauer 23 report increasing resting hand tremor for 
cocaine users following 12 weeks of abstinence, while the resting hand tremor of alcohol 
users reduced over the 12-week period. The authors suggest that these results may be 
indicative of extrapyramidal dysfunction in cocaine users.  Finally, following one year of 
cocaine and/or amphetamine abstinence, motor skills were more impaired for past users 
compared to their non-using twin24. 
The aim of the present study was to investigate the potentially harmful sub-acute and 
chronic effects of heavy stimulant drug use on psychomotor control. Based on previous 
research we hypothesized that deficits in psychomotor control, specifically arm-droop and 
tremor, would be greater for current and former stimulant drug users compared to non-users, 
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and that these deficits would be enduring, with no difference in arm-droop and tremor 
expected between current and former drug using groups. 
 
Materials and Methods 
Ethics Statement 
The ethics committee of the Department of Psychology at Swansea University approved the 
between-subject study design in accordance with the Declaration of Helsinki and all 
participants provided written informed consent. 
 
Participants 
Sixty participants who were not undertaking nor seeking any medical treatment and were free 
from any neurological condition volunteered for this study. There were three experimental 
groups: current stimulant users (CSU: N= 20, males= 11, age= 18-45, M(SD)= 31.4(9.1)), 
former stimulant users (FSU: N= 20, males= 5, age= 20-55, M(SD)= 39.1(8.5)) and non-user 
controls (NUC: N= 20, males= 5, age= 18-63, M(SD)= 35.7(16.4)).  
The inclusion criteria for the CSU and FSU groups were that they used at least one of 
four recreational stimulant drugs (amphetamine, MDMA, cocaine or mephedrone) at least 
twice per week for a minimum of two years. The FSU group were also required to have been 
abstinent from stimulants for at least 18 months prior to the study. It should be noted that 
participants were poly-drug users, and many reported having taken MDMA (around 50%) 
and/or amphetamine (around 85%) intravenously. To our knowledge, intravenous poly-drug 
use has not been empirically investigated previously. The inclusion criterion for the NUC was 
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of no history of illicit drug use. Tobacco smoking was allowed to prevent any nicotine 
withdrawal symptoms affecting the results.   
 
Experimental Protocol  
All participants completed the University of East London Recreational Drug Use 
Questionnaire to quantify lifetime drug usage25; drug usage characteristics of the three groups 
are shown in Table 1. All participants wore an X6-2A USB accelerometer (Gulf Coast Data 
Concepts, LLC, Waveland, USA) attached in a standardized manner to the dorsal surface of 
the wrist of their dominant hand (Figure 1a). The device recorded acceleration in three 
orthogonal axes X, Y and Z (also termed sway, surge and heave, respectively, Figure 1a) at 80 
Hz with a resolution of 16-bit and a recording range of ±6.0 g (acceleration of gravity). The 
participants were then asked to hold their dominant arm in one of 10 positions (all horizontal, 
perpendicular to the body), one at a time, and maintain the position for 60 seconds at each 
position. Participants were given a 30-second rest between each arm position. The arm 
positions were carried out in the following order: 
 Position 1. Sitting upright on a chair, both arms extended forward and parallel to each other. 
 Position 2. Remaining seated, extending arms to the sides. 
 Position 3 and 4. Position 1 and 2 repeated while standing upright. 
 Position 5. Standing upright, only dominant hand extended forward holding a pen between 
index finger and thumb. 
 Position 6 to 10. Position 1 to 5 repeated with eyes closed. 
See Figure 1b for an example of the raw accelerometry data of a single NUC participant 
during position 1. 
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Data Analysis  
Accelerometry data was first smoothed with a running mean over 2 seconds for each of the 
three axes (x, y, z). This method of smoothing resulted in the ‘static’ or gravity-based 
component of acceleration, which was an indication of the posture of the arm in relation to the 
horizon26. The ‘dynamic’ acceleration, or muscular activity, of the participant’s arm was 
calculated by subtracting the static acceleration from the raw acceleration values (cf.19). The 
Vector of Dynamic Body Acceleration (VeDBA), which was representative of all 3-
dimensional motion made by the participants, was then calculated by taking the square root of 
the added squares of the dynamic acceleration data from the three axes (x, y and z; cf.27). 
VeDBA therefore provided a measure of participants’ arm tremor. The motion detected on the 
y-axis only (Arm Longitudinal Rotation Axis; ALoRA), represented the extent to which the 
participant’s arm-droops while attempting to maintain steady arms in front of the body (see 
Figure 1a).  
 
Statistical Analysis  
Descriptive statistics of the ALoRA and VeDBA axes were calculated for each participant and 
later converted from standard acceleration of gravity (g) to degrees (°) for a clearer indication 
of arm motion; a value of 0° indicated a perfectly horizontal position. The grand mean 
interquartile range (IQR) was then calculated for each group. Four multivariate analyses of 
variance (MANOVA) were conducted to investigate group differences in IQR for ALoRA 
and VeDBA in eyes open and eyes closed conditions separately. Experimental group 
differences in age, sex and lifetime drug use were analysed using analysis of variance 
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(ANOVA) for continuous variables, and chi-square for categorical variables. Kruskal-Wallis 
H tests were used where the assumptions of an ANOVA were not met. All statistics were 
carried out using SPSS version 2228. 
 
Results 
Demographic Differences 
A one-way ANOVA revealed no differences between the three groups in age (M(SD):  NDT= 
35.7(16.0), CSU= 31.4(8.9), FSU= 39.1(8.3); F(2, 57)= 2.13, p= 0.128), and a chi-square test 
observed no significant group difference in sex ratio (X2(2)= 5.28, p= 0.072). A two-way 
(group x drug) ANOVA investigating the differences in lifetime stimulant usage between the 
CSU and FSU groups revealed no significant difference between the groups on overall 
lifetime drug use (F(1, 494)= 0.137, p= 0.711), however, there was a significant difference in 
lifetime use between the type of drug used, with amphetamines and MDMA far more 
commonly used than the other drug types (see Table 1). There was no group by drug 
interaction, suggesting the groups did not differ in their use of specific drug types significant 
(F(12, 494)= 0.27, p= 0.995). 
A Kruskal-Wallis H test showed that there was a significant difference between the 
three groups in their use of tobacco (H(2)= 17.75, p < 0.001) and cannabis (H(2)= 11.37, p= 
0.003). This difference was driven by the NUC group containing only two smoking and no 
cannabis-using participant; there was no difference between CSU and FSU groups 
consumption of tobacco (X2(1)= 0.100, p= 0.752) or cannabis (X2(1)= 1.758, p= 0.185). There 
was no significant difference between the three groups in alcohol consumption (X2(2)= 1.200, 
p= 0.549).   
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Accelerometry Differences 
The comparative psychomotor performance of the three groups can be seen in Table 2. 
Overall, there were widespread differences between the groups for both ALoRA (arm-droop) 
and VeDBA (tremor) measures. The CSU group had the highest mean acceleration angle 
scores with largest standard deviation values, followed by the FSU group and then the NUC 
group.  
ALoRA IQR results from positions 1 to 5 (eyes open) show that both stimulant using 
groups ‘droop’ their arms below horizontal more than the NUC group, and the MANOVA 
demonstrated this difference was significant with a significant main effect for group (F(10, 
108)= 1.98, p < 0.05; Pillai’s Trace= 0.309, 2= 0.16). Post-hoc analyses revealed that the 
group difference was driven by increased ALoRA for positions 3 (F(2, 57)= 3.88, p < 0.05; 
2= 0.12) and 4 (F(2, 57)= 4.29, p < 0.05; 2= 0.13), and a trend for position 5; (F(2, 57)= 
3.03, p= 0.056; 2= 0.10). The MANOVA of ALoRA IQRs for the eyes-closed arm positions 
(i.e., positions 6 to 10) again indicated a significant main effect for group (F(10, 108)= 2.03, p 
< 0.05; Pillai’s Trace= 0.317, 2= 0.16). Post-hoc analyses revealed significant increase in 
ALoRA for the stimulus using groups in positions 6 (F(2, 57)= 4.59, p < 0.05; 2= 0.14), 7 
(F(2, 57)= 4.90, p < 0.05; 2= 0.15), and 9 (F(2, 57)= 3.46, p < 0.05; 2= 0.11), and reduced 
ALoRA for the FSU group for position 10 (F(2, 57)= 3.47, p < 0.05; 2= 0.11). Tukey HSD 
post-hoc group comparisons revealed significant differences between NUC and CSU for 
positions for positions 3, 4, 6, 7 and 9, and between CSU and FSU for positions 4 and 10; 
these comparisons are presented in Table 2. 
More striking were the differences in tremor as represented by the VeDBA axis of 
 10 
each of the 10 positions. The CSU and FSU VeDBA scores were higher during each position 
of the eyes-open condition, indicating more tremor, and the MANOVA indicated this 
difference between groups to be significant (F(10, 108)= 4.46, p < 0.001; Pillai’s Trace= 
0.585, 2= 0.29). Post-hoc analyses revealed the increase to be driven by significant 
differences for each of the five positions; position 1 (F(2, 57)= 18.80, p < 0.001; 2= 0.40), 2 
(F(2, 57)= 12.16, p < 0.001; 2= 0.30), 3 (F(2, 57)= 6.91, p < 0.01; 2= 0.20), 4 (F(2, 57)= 
7.65, p < 0.01; 2= 0.21), and 5; (F(2, 57)= 6.73, p < 0.01; 2= 0.19). VeDBA scores were 
also greater for each of the five positions during the eyes-closed condition; the MANOVA 
indicated the increase was significant (F(10, 108)= 2.53, p < 0.01; Pillai’s Trace= 0.379, 2= 
0.19). Post-hoc analyses revealed the significant group main effect to be driven by significant 
differences at each of the five positions; 6 (F(2, 57)= 6.83, p < 0.01; 2= 0.19), 7 (F(2, 57)= 
11.93, p < 0.001; 2= 0.30), 8 (F(2, 57)= 7.07, p < 0.01; 2= 0.20), 9 (F(2, 57)= 6.13, p < 
0.01; 2= 0.18), and 10 (F(2, 57)= 8.89, p < 0.001; 2= 0.24). Overall VeDBA for all 10 
positions was significantly larger for CSUs than NUCs, whilst VeDBA for positions 1, 2, 3, 5, 
6, 7 was lager for FSUs than for NUCs, and only VeDBA in position 1 was significantly 
different between CSU and FSU. The Tukey HSD comparisons for positions 1 to 10 are 
presented in Table 2. 
Discussion 
This study observed significant psychomotor control deficits in current and former 
recreational users of stimulant drugs compared to non-user controls. As predicted, tremor 
(VeDBA) was larger for current users compared to non-users for each of the ten positions. 
Former users also demonstrated larger tremor than non-users, however, the increase was only 
statistically significant for six of the ten positions (four with eyes open and two with eyes 
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closed). There were fewer arm-droop (ALoRA) deficits observed for current users, while no 
significant deficits were observed for the former users compared to non-users. Finally, as 
predicted, tremor and arm-droop did not differ between current and former users, except in 
three of the 20 positions where there was increased deficit for current users: VeDBA in the 
first position, ALoRA in the fourth position and ALoRA in the tenth position. Overall, these 
findings indicate impairments in both tremor and arm-droop in heavy stimulant users, and that 
tremor, but not arm-droop, persists for at least 18 months following withdrawal from 
stimulant use.  
These data suggest that the effect of stimulant use on tremor endures for over 18 
months of abstinence, with all but one position eliciting a similarly high degree of tremor 
between current and former stimulant users. These findings are somewhat supported by 
research reporting enduring tremor after a 12-week washout of cocaine, which was suggested 
to indicate extrapyramidal dysfunction in these users23.  Former users displayed less tremor 
than current users for the first position of this study, and tremor was comparable between 
former and non-users for four of the ten positions, suggesting some degree of recovery from 
the acute effects of stimulant drug use over 18 months of abstinence. 
In terms of arm-droop, results suggest poorer proprioceptive functionality for current 
users compared to non-users for most positions, and compared to former users for two 
positions. Unlike tremor, proprioception appears to improve over time, with no significant 
differences in arm-droop between former users and non-users. These findings suggest that 
stimulant users recover their proprioceptive capacity over a period of time of abstinence.  
Deficits in motor dexterity and speed have been reported to continue for former 
stimulant users following one year of abstinence, however, these were within normal limits24. 
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Psychomotor deficits can lead to a range of adverse implications for everyday tasks, including 
social functioning, interpersonal communication, and performance on simple and complex 
motor tasks, and the detection of psychomotor deficiencies might be considered an early 
marker for movement disorders29.  These outcomes pose significant health and safety risks for 
stimulant drug users30,31, highlighting the need for better management of prevention and 
recovery programs for stimulant drug use. 
The current findings are broadly consistent with previous research suggesting that 
stimulant drug use leads to tremor and psychomotor movement abnormalities through their 
effect on dopaminergic and serotonergic pathways (i.e., stimulants)1,3,20,29,32, Parrott, 2013 #549. For 
example, the acute effects of MDMA have been shown to include tics, twitches, tremors and 
shakes13,14,. Furthermore, 38% of heavy MDMA users report psychomotor problems, which 
they attribute to MDMA use15,33.  
Although arm droop and tremor differences between current, former and non-drug 
users were observed in this study, it is unclear whether these directly predict the degree of 
movement deficit in clinical populations as no studies to date employ ALoRA and VeDBA as 
measurement indices. Work by Flavel, Koch, White, Todd 20 suggests that increased tremor 
might mark motor abnormalities and the future development of movement disorders, as 
stimulant use has been associated with later diagnosis of conditions such as tics, dystonia and 
essential tremor. Wilson, Grundy, Massy, Soltis, Tysse, Holton, Cai, Parrott, Downey, 
Qasem, Butt 18 suggests that abnormalities in micro-movements may index later development 
of movement disorder in non-clinical populations, as MDMA has been associated with 
aberrant serotonin transportation, and  serotonergic disruption has been associated with 
movement disorder9. 
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Differences observed between the eyes-open and eyes-closed tasks may be attributed 
to motion perception ability. The physiological control of body position and movement 
involves multiple neural processes, requiring visual and proprioceptive cues34. In the eyes-
closed condition, visual cues are removed, increasing the load on proprioceptive function, 
suggesting that a higher degree of arm movement is associated with a proprioceptive deficit. 
Therefore, this study suggests sub-acute proprioceptive deficits for stimulant users that appear 
to improve over time for some positions.  
There are some limitations of this study that require mention. First, cannabis and 
tobacco (nicotine) consumption differed between the experimental groups. Cannabis use has 
been suggested to reduce serotonin neurotoxicity, thus ameliorate the effects of MDMA on 
pathways involved in psychomotor movement10,35. Current users were shown to consume 
more cannabis than former users, who in turn consumed more than non-users, thus it is 
possible that the psychomotor differences between the groups may have been larger in the 
absence of cannabis use. It should be noted, however, that the ratio of cannabadiol and THC 
in cannabis is highly variable, and as such the extent that recreational cannabis might reduce 
neurotoxicity remains unknown. Nicotine consumption was higher for both stimulant user 
groups compared to non-users, and nicotine has been shown to enhance the locomotor effects 
of amphetamines and dopamine pathways in rats36. It is therefore possible that nicotine 
differences between the stimulant using and non-using groups is exacerbated by nicotine 
consumption. Second, participants within the stimulant user groups were typically poly-drug 
users, which is common among the general user population7,37. Parrot et al., (2017, in press) 
suggests that poly-drug use is a significant problem for research into the effects of 
recreational drugs, it is therefore difficult to ascribe the findings of psychomotor deficit to any 
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one particular drug38. Third, we relied on self-report stimulant use and did not test compliance 
of abstinence with blood or urine samples. It is possible that some participants were affected 
by stimulants at the time of the study, which may have resulted in increased tremor 10.  
Finally, the age difference between current and former users was substantial; the ratio of 
females to males was 2.5:1 for former users and non-users, and there was an 8-year mean age 
difference between current and former stimulant users. There are no studies investigating sex 
and age differences in VeDBA and ALoRA measure, however, it is unlikely tremor and arm-
droop would be significantly impacted across the 10-year age-span. Nevertheless, these data 
demonstrate psychomotor characteristics that are present in the non-clinical drug using 
community, and are thus an important contribution to the literature at large. 
In conclusion, this study used accelerometry to demonstrate significant psychomotor 
deficits for current users of recreational stimulant drugs. These deficits appear to persist for at 
least 18 months following cessation of stimulant drug taking. The physical effects of 
stimulant drugs might manifest from serotonin and dopamine pathway disruption caused by 
the drugs, however, there appears to be a degree of recovery, with former users performing 
better than their current user counterparts on a number of psychomotor positions. Having 
detected a degree of recovery for former users, accelerometer devices have the potential to 
become an important predictor of adverse effects that may lead to long-term psychological 
and psychomotor damage. In this way, metrics such as tremor and arm-droop could be used as 
valid risk markers for the development of movement disorders.  
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Table 1: Percentage and mean(SD) use of drugs for each experimental group 
 Percent users(%) Average usage(mean(SD)) 
 NUC CDU FDU NUC CDU FDU 
MDMA 0 85 90 0(0) 276.4(335.1) 350.9(330.2) 
MDMA(IV) 0 65 50 0(0) 0.6(0.4) 0.5(0.5) 
Amphetamine 0 90 100 0(0) 565(412.6) 532.4(325.7) 
Amphetamine(IV) 0 85 95 0(0) 0.8(0.3) 0.9(0.2) 
Cocaine(nasal) 0 60 65 0(0) 36.7(107.3) 36.7(51.3) 
Cocaine(IV) 0 35 35 0(0) 0.3(0.4) 0.3(0.4) 
Cocaine(crack) 0 40 25 0(0) 5.6(12.2) 9.5(23.9) 
Crack(IV) 0 0 5 0(0) 0(0) 0(0) 
LSD 0 30 35 0(0) 1.3(2.8) 9(23.3) 
LSD(IV) 0 0 5 0(0) 0(0) 0(0) 
Mephedrone 0 45 25 0(0) 2.3(3.2) 3.2(7.6) 
Mephedrone(IV) 0 15 10 0(0) 0.1(0.3) 0.1(0.3) 
Opiates 5 10 5 0.1(0.4) 0.2(0.6) 0.2(1) 
Opiates(IV) 5 0 0 0(0) 0(0) 0(0) 
Benzodiazepines 0 0 10 0(0) 0(0) 1(3) 
Benzodiazepines(IV) 0 0 5 0(0) 0(0) 0(0) 
Magic mushrooms 0 40 20 0(0) 1.6(4.3) 6.1(21.9) 
Magic mushrooms(IV) 0 0 5 0(0) 0(0) 0(0) 
Anabolic steroids 0 0 0 0(0) 0(0) 0(0) 
Anabolic steroids(IV) 0 0 0 0(0) 0(0) 0(0) 
Solvents 0 15 15 0(0) 0.9(2.7) 0.8(2.3) 
Solvents(IV) 0 0 5 0(0) 0(0) 0(0) 
Poppers 0 30 40 0(0) 11.5(43.4) 12.7(24.2) 
Poppers(IV) 0 0 5 0(0) 0(0) 0(0) 
Ketamine 0 15 15 0(0) 0.2(0.5) 0.2(0.6) 
Ketamine(IV) 0 0 10 0(0) 0(0) 0(0.2) 
Tobacco 10 70 65 0.7(2.3) 5.2(4.2) 4.6(4.6) 
Alcohol 65 65 65 3.1(3.4) 3.7(3.8) 4.8(3.8) 
Cannabis 0 45 25 0(0) 3.7(5.3) 1.5(2.8) 
Note: NUC = non-user controls, CSU = current stimulant users, FSU = former stimulant users, 
MDMA = 3,4-methylenedioxymethamphetamine, LSD = Lysergic acid diethylamide, IV = 
intravenous. Averages for stimulant drugs are lifetime use, tobacco is cigarettes per day, alcohol 
is units per week, and cannabis is use per month. 
 
 20 
Table 2. Mean(SD) interquartile ranges in degrees (°) of the two motion axes, Arm Longitudinal 
Rotation Axis (ALoRA) and Vector of Dynamic Body Acceleration (VeDBA) during the 10 
different arm activities. 
Activity NUC  CSU FSU  
ALoRA eyes open 
1 2.37(1.52) 2.52(1.53) 2.85(1.53) 
2 3.36(1.80) 3.30(1.91) 3.04(1.47) 
3 2.35(1.56) 3.91(2.27) * 2.72(1.64) 
4 2.87(1.66) 4.22(2.26) *# 2.73(1.29) 
5 1.95(1.57) 3.27(2.27) 3.09(1.59) 
ALoRA eyes closed 
6 2.27(1.92) 4.14(2.59) * 2.74(1.41) 
7 2.64(1.52) 6.45(6.37) * 3.81(1.96) 
8 2.59(1.70) 3.50(2.23) 3.64(2.84) 
9 2.96(1.77) 4.40(1.74) * 3.51(1.74) 
10 3.55(2.66) 4.74(2.39) # 2.93(1.32) 
VeDBA eyes open 
1 0.34(.11) 0.79(.32) *# 0.57(.20) * 
2 0.36(.11) 1.04(.66) * 0.78(.37) * 
3 0.38(.12) 0.91(.68) * 0.74(.38) * 
4 0.45(.18) 1.17(.92) * 0.74(.40) 
5 0.44(.22) 0.82(.40) * 0.79(.65) * 
VeDBA eyes closed 
6 0.56(.28) 0.93(.29) * 0.82(.40) * 
7 0.43(.14) 1.01(.51) * 0.81(.39) * 
8 0.49(.19) 0.88(.45) * 0.67(.29) 
9 0.49(.17) 1.15(.94) * 0.76(.41) 
10 0.42(.19) 0.92(.51) * 0.70(.34) 
Note: CSU = current stimulant users, FSU = former stimulant users, NUC = non-user controls. * 
= significantly different from NUC, # = significantly different from FSU.  
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Figure 1. a) Position of the accelerometer device and its three orthogonal axes X, Y and Z 
(which measure sway, surge and heave motions respectively) as attached to the wrist of the 
subject’s dominant hand. The Arm Longitudinal Rotation Axis (ALoRA) is denoted by the Y-
axis and records arm steadiness. This is measured as the change in arm position as it deviates 
from horizontality of 0° or in other words, the degree of ‘arm-drop’. The more the participant 
deviates from an arm position of 0°, the more it implies psychomotor difficulties.  b) Example of 
the raw accelerometry signal as seen in axes X, Y and Z, showing activities 1 to 5 as carried out 
(with eyes open) by a non-user participant. Looking at the Y-axis, the signal can be seen 
‘dropping’ during the five activities, indicating a normal level of arm-drop due to muscle fatigue 
(these levels were much more pronounced for both current and former stimulant users). 
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